Protocol
Therapeutic plasma exchange (TPE)
Plasmapheresis · Therapeutic plasmapheresis · Plasma exchange · TPE
TPE has decades of genuine clinical evidence for established medical indications (myasthenia gravis, demyelinating disease, thrombotic thrombocytopenic purpura, hyperviscosity syndromes, anti-GBM disease), which is why HSA's Blood Services Group runs it as a hospital service in Singapore. That evidence does not transfer to healthy ageing. The best longevity-specific data is a single randomised, single-blinded, placebo-controlled trial of 42 adults over 50 (Fuentealba et al., Aging Cell, 2025), with four arms: biweekly TPE plus IVIG, biweekly TPE alone, monthly TPE, and placebo. The TPE-IVIG arm showed rejuvenation on 15 epigenetic clocks versus placebo (FDR < 0.05), alongside coordinated shifts in proteomic, metabolomic, glycomic, and immune-cell markers. Every one of these endpoints is a molecular surrogate. The trial measured no functional, disease-incidence, healthspan, or mortality outcome, so it does not show that anyone lived longer or better. It is also small (n=42), single-blinded rather than double-blinded, and industry-linked (run with a commercial TPE provider). Two further honest caveats: the effect was largest in the arm that added IVIG, meaning the plasma exchange alone is not clearly the active ingredient; and TPE is not risk-free, carrying citrate reactions, hypotension, vascular access complications, and albumin/immunoglobulin depletion. A material correction to earlier scoping: Monash House Private Hospital in Melbourne does explicitly list "Healthy Longevity" among the indications for which its doctors may recommend TPE, so this is being marketed for longevity in Australia, not only for medical indications. However Monash House is a private hospital, not one of the named longevity clinics, and no clinic on either the Singapore or Australia list was confirmed to offer TPE. Net: real clinical drug for real diseases, surrogate-only and commercially promoted as a longevity protocol.
At a glance
- Evidence
- Commercial
- Singapore (HSA)
- Not verified as approved for any anti-ageing or longevity indication; treat as unapproved for that use. What is verified: HSA's Blood Services Group itself provides therapeutic plasma exchange to hospital patients using apheresis technology, for established medical indications including myasthenia gravis, demyelinating diseases, anti-glomerular basement membrane antibody disease, cryoglobulinaemia, multiple myeloma with hyperviscosity, thrombotic thrombocytopenic purpura, and post-transfusion purpura. That is HSA operating as a clinical service provider for disease indications, not HSA authorising TPE as a healthspan intervention. No HSA authorisation, registration, or guidance covering TPE for ageing was located.
- Australia (TGA)
- Not verified from the TGA; no TGA authorisation for an anti-ageing or longevity indication was located. Structural note, stated conservatively: TPE is a medical procedure rather than a therapeutic good, so it is not itself entered on the ARTG; the TGA's remit covers the apheresis devices, consumables, and plasma-derived products used to perform it. In practice TPE is delivered in Australia as a prescription-only medical procedure in hospital settings by clinicians with specialist apheresis training. Monash House Private Hospital (Melbourne) markets it under listed indications that include "Healthy Longevity" alongside autoimmune, neurological, and haematological conditions and Long COVID. Regulatory status for the longevity use returned as unverified rather than guessed.
- Offered at
- No clinic on file
Singapore
Health Sciences Authority
- HSA status
- Not verified as approved for any anti-ageing or longevity indication; treat as unapproved for that use. What is verified: HSA's Blood Services Group itself provides therapeutic plasma exchange to hospital patients using apheresis technology, for established medical indications including myasthenia gravis, demyelinating diseases, anti-glomerular basement membrane antibody disease, cryoglobulinaemia, multiple myeloma with hyperviscosity, thrombotic thrombocytopenic purpura, and post-transfusion purpura. That is HSA operating as a clinical service provider for disease indications, not HSA authorising TPE as a healthspan intervention. No HSA authorisation, registration, or guidance covering TPE for ageing was located.
- In our SG set
- Tracked in Singapore
- SG clinics
- None on file
Australia
Therapeutic Goods Administration
- TGA status
- Not verified from the TGA; no TGA authorisation for an anti-ageing or longevity indication was located. Structural note, stated conservatively: TPE is a medical procedure rather than a therapeutic good, so it is not itself entered on the ARTG; the TGA's remit covers the apheresis devices, consumables, and plasma-derived products used to perform it. In practice TPE is delivered in Australia as a prescription-only medical procedure in hospital settings by clinicians with specialist apheresis training. Monash House Private Hospital (Melbourne) markets it under listed indications that include "Healthy Longevity" alongside autoimmune, neurological, and haematological conditions and Long COVID. Regulatory status for the longevity use returned as unverified rather than guessed.
- In our AU set
- Tracked in Australia
- AU clinics
- None on file
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.
What it is
Plain-language explainer
Therapeutic plasma exchange is an extracorporeal blood procedure in which a patient's plasma is separated from their blood cells by an apheresis machine, removed, and replaced with albumin, saline, or donor plasma. It is a long-established hospital treatment for a defined set of autoimmune, neurological, and haematological conditions. Its longevity application rests on a separate claim: that removing circulating age-associated proteins and inflammatory factors, sometimes paired with intravenous immunoglobulin, can lower measured biological age.
Categories
Protocol
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Clinical support services: therapeutic apheresis and plasma exchange · Health Sciences Authority (HSA), Singapore
- Therapeutic Plasma Exchange (TPE) · Monash House Private Hospital, Melbourne
- Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange · Aging Cell (2025), via PubMed
Every entity profile on variis is sourced. Not medical advice.